A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs ARQ 761 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Status changed from recruiting to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History